Amaç: Bu çalışmada, berberin-klorürün antikanser etkinliğinin, 2 farklı kanser hücre hattında (MCF-7 meme kanseri hücreleri ve M4A4 metastatik meme kanseri hücreleri) analiz edilmesi ve antibakteriyel etkinliğinin 5 farklı standart bakteri suşunda araştırılması amaçlanmıştır. Gereç ve Yöntemler: Çalışmada, MCF-7 meme kanseri hücreleri ve M4A4 metastatik meme kanseri hücreleri olmak üzere 2 hücre hattına karşı MTT analizi uygulanarak, berberin-klorürün zamana bağlı oluşturduğu inhibisyon araştırılmıştır. Ayrıca berberin-klorürün 6 standart suş [Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, 'methicillin resistant S. aureus (MRSA)', Pseudomonas aeruginosa ve Enterococcus faecalis) kullanılarak antibakteriyel etkisi broth mikrodilüsyon ve agar zon difüzyon yöntemleri ile analiz edilmiştir. Bulgular: MCF-7 hücreleri için hücre canlılığının %50 inhibe olduğu konsantrasyon, 72 saatlik berberin-klorür muamelesi sonrası 19,57 µM, M4A4 hücreleri için ise 77,7 µM olarak bulunmuştur. Broth mikrodilüsyon testinde minimum inhibitör konsantrasyonu değerleri, S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa ve E. faecalis için sırasıyla 0,49 µg/mL, 0,98 µg/mL, 0,0038 µg/mL, 3,91 µg/mL, 0,03 µg/mL ve 0,49 µg/mL olarak bulunmuştur. Agar kuyucuk difüzyon testinde zon inhibisyon değerleri S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa ve E. faecalis için sırasıyla 30 mm, 30 mm, 35 mm, 17 mm, 33 mm ve 20 mm olarak bulunmuştur. Sonuç: Çalışmada, berberinklorürün farklı hücre hatlarına antikanser etkisi ve yaygın olarak enfeksiyona sebep olan bakterilere karşı antibakteriyel etkinliği olduğu in vitro olarak gösterilmiştir.
Anahtar Kelimeler: Berberin-klorür; antibakteriyel; antikanser; sitotoksisite; MTT analizi
Objective: In this study, it was aimed to analyse the anti-cancer activity of berberine-chloride in two different cancer cell lines (MCF-7 breast cancer cells and M4A4 metastatic breast cancer cells) and to investigate the antibacterial activity in five different standard bacterial strains. Material and Methods: In the study, the timedependent inhibition by berberine chloride was investigated by applying MTT assay against two cell lines, which are MCF-7 breast cancer cells and M4A4 metastatic breast cancer cells. In addition, the anti-bacterial effect of berberine chloride was analysed by using six standard strains [Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, methicillin resistant S. aureus (MRSA), Pseudomonas aeruginosa and Enterococcus faecalis] with the broth microdilution and agar zone diffusion methods. Results: The concentration at which cell viability was 50% inhibited for MCF-7 cells after 72 hours of berberine chloride treatment was found to be 19.57 µM and 77.7 µM for M4A4 cells. Minimum inhibitory concentration values in broth microdilution test for S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa and E. faecalis, was found to be 0.49 µg/mL, 0.98 µg/mL, 0.0038 µg/mL 3.91 µg/mL, 0.03 µg/mL and 0.49 µg/mL respectively. Zone inhibition values in agar well diffusion test was found as 30 mm, 30 mm, 35 mm, 17 mm, 33 mm and 20 mm for S. aureus, MRSA, E. coli, K. pneumoniae, P. aeruginosa and E. faecalis, respectively. Conclusion: In the study, berberine-chloride anti-cancer effect on different cell lines and antibacterial activity against commonly infectious bacteria has been shown in-vitro.
Keywords: Berberine chloride; anti-bacterial; anti-cancer; cytotoxicity; MTT assay
- Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat. 2013;138(3):665-73. [Crossref] [PubMed]
- Tan W, Li Y, Chen M, Wang Y. Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine. 2011;6:1773-7. [Crossref] [PubMed] [PMC]
- Affuso F, Mercurio V, Fazio V, Fazio S. Cardiovascular and metabolic effects of berberine. World J Cardiol. 2010;2(4):71-7. [Crossref] [PubMed] [PMC]
- Wang X, Feng S, Ding N, He Y, Li C, Li M, et al. Anti-inflammatory effects of berberine hydrochloride in an LPS-induced murine model of mastitis. Evid Based Complement Alternat Med. 2018;2018:5164314. [Crossref] [PubMed] [PMC]
- Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449-61. [Crossref] [PubMed]
- Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-92. [Crossref] [PubMed]
- Li X, Zhao SJ, Shi HL, Qiu SP, Xie JQ, Wu H, et al. Berberine hydrochloride IL-8 dependently inhibits invasion and IL-8-independently promotes cell apoptosis in MDA-MB-231 cells. Oncol Rep. 2014;32(6):2777-88. [Crossref] [PubMed]
- Chen C, Yu Z, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract-a review of actions and therapeutic implications. Am J Chin Med. 2014;42(5):1053-70. [Crossref] [PubMed]
- Hu Q, Li L, Zou X, Xu L, Yi P. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma. Front Pharmacol. 2018;9:1150. [Crossref] [PubMed] [PMC]
- Liu H, Huang C, Wu L, Wen B. Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer. Onco Targets Ther. 2016;9:4121-7. [Crossref] [PubMed] [PMC]
- Tian Y, Zhao L, Wang Y, Zhang H, Xu D, Zhao X, et al. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. Asian J Androl. 2016;18(4):607-12. [Crossref] [PubMed] [PMC]
- Sun Y, Wang W, Tong Y. Berberine inhibits proliferative ability of breast cancer cells by reducing metadherin. Med Sci Monit. 2019;25: 9058-66. [Crossref] [PubMed] [PMC]
- Li J, Liu F, Jiang S, Liu J, Chen X, Zhang S, et al. Berberine hydrochloride inhibits cell proliferation and promotes apoptosis of non-small cell lung cancer via the suppression of the MMP2 and Bcl-2/Bax signaling pathways. Oncol Lett. 2018;15(5):7409-14. [Crossref]
- Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol. 2010;645(1-3):70-8. [Crossref] [PubMed]
- Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. M26-A Methods for determining bactericidal activity of antimicrobial agents; approved guideline. National Committee for Clinical Laboratory Standards. 1999;19(18):1-29. http://demo.nextlab.ir/getattachment/096a51d4-1530-4f81-92c0-f5477c584b9b/CLSI-M26-A.aspx
- Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504-23. [Crossref] [PubMed]
- Xiao D, Liu Z, Zhang S, Zhou M, He F, Zou M, et al. Berberine derivatives with different pharmacological activities via structural modifications. Mini Rev Med Chem. 2018;18(17): 1424-41. [Crossref] [PubMed]
- Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139-57. [Crossref] [PubMed]
- Tan W, Zhong Z, Wang S, Suo Z, Yang X, Hu X, et al. Berberine regulated lipid metabolism in the presence of C75, compound C, and TOFA in breast cancer cell line MCF-7. Evid Based Complement Alternat Med. 2015;2015:396035. [Crossref] [PubMed] [PMC]
- Guamán Ortiz LM, Croce AL, Aredia F, Sapienza S, Fiorillo G, Syeda TM, et al. Effect of new berberine derivatives on colon cancer cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(10):824-33. [Crossref] [PubMed]
- Chen Q, Qin R, Fang Y, Li H. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell Physiol Biochem. 2015;36(3):956-65. [Crossref] [PubMed]
- Liu D, Meng X, Wu D, Qiu Z, Luo H. A natural isoquinoline alkaloid with antitumor activity: studies of the biological activities of berberine. Front Pharmacol. 2019;10:9. [Crossref] [PubMed] [PMC]
- Hussein SAM, Barakat HH, Merfort I, Nawwar MAM. Tannins from the leaves of Punica granatum. Phytochemistry. 1997;45(4):819-23. [Crossref]
- Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343-56. [Crossref] [PubMed] [PMC]
- Zuo GY, Li Y, Han J, Wang GC, Zhang YL, Bian ZQ. Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant Staphylococcus aureus (MRSA). Molecules. 2012;17(9):10322-30. [Crossref] [PubMed] [PMC]
- Hong SB, Rhee MH, Yun BS, Lim YH, Song HG, Shin KS. Synergistic anti-bacterial effects of phellinus baumii ethyl acetate extracts and β-lactam antimicrobial agents against methicillin-resistant Staphylococcus aureus. Ann Lab Med. 2016;36(2):111-6. [Crossref] [PubMed] [PMC]
- Du GF, Le YJ, Sun X, Yang XY, He QY. Proteomic investigation into the action mechanism of berberine against Streptococcus pyogenes. J Proteomics. 2020;215:103666. [Crossref] [PubMed]
- Adamczak A, Ożarowski M, Karpiński TM. Antibacterial activity of some flavonoids and organic acids widely distributed in plants. J Clin Med. 2019;9(1):109. [Crossref] [PubMed] [PMC]
- Tan J, Wang J, Yang C, Zhu C, Guo G, Tang J, et al. Antimicrobial characteristics of berberine against prosthetic joint infection-related Staphylococcus aureus of different multi-locus sequence types. BMC Complement Altern Med. 2019;19(1):218. [Crossref] [PubMed] [PMC]
- Pierpaoli E, Cirioni O, Simonetti O, Orlando F, Giacometti A, Lombardi P, et al. Potential application of berberine in the treatment of Escherichia coli sepsis. Nat Prod Res. 2020;1-6. [Crossref] [PubMed]
- Shi C, Li M, Muhammad I, Ma X, Chang Y, Li R, et al. Combination of berberine and ciprofloxacin reduces multi-resistant Salmonella strain biofilm formation by depressing mRNA expressions of luxS, rpoE, and ompR. J Vet Sci. 2018;19(6):808-16. [Crossref] [PubMed] [PMC]
- Xu Y, Quan H, Wang Y, Zhong H, Sun J, Xu J, et al. Requirement for ergosterol in berberine tolerance underlies synergism of fluconazole and berberine against fluconazole-resistant Candida albicans isolates. Front Cell Infect Microbiol. 2017;7:491. [Crossref] [PubMed] [PMC]
.: Process List